Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPNS versus usual care for predictable swallowing breakthrough pain during radiotherapy in head and neck cancer
2015-005110-30Phase 4Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fentanyl in breakthrough cancer pain (BTcP) and head and neck cancer (HNC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Nov 2020; status: terminated.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2015-005110-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005110-30.